Dr Reddys Laboratories Ltd

BSE :500124 NSE :DRREDDY Sector : Pharmac..
1,107.95
Change: 2.80(0.25%)
52 week Low
1,092.45
52 week High
1,421.49
Day low
1,095.05
Day high
1,110.25
Prev Close
1,105.15
Open
1,105.15
6M return
-16.83%
1Y return
-12.12%
MCap(Rs. in Cr.)
92,452.24
Total Volume
12,99,174
Face Value : 1
Listed Since
PE Ratio

Is the price-earnings ratio for valuing a company that measures its current share price relative to its earnings per share.

P/E RATIO
17.21066
EPS

The earnings per share ratio is a portion of company's net profit allocated for each outstanding share. It is calculated by deducting preferred stock divided from the net income of the company divided by the number of outstanding shares.

EPS
64.37
PRICE/BOOK

Price-to-book ratio is used to compared the company's current market price with its book value.

PRICE/BOOK
3.01
Deliverable

These are the acutal number of shares that are traded on delivery based, meaning transfered from one person to another during the day's trade.

DELIVERABLES
62.13%
DIV YIELD.(%)

Dividend Yield measures the quantum of cash dividends paid to shareholders in a financial year relative to the market value of the per share.

DIV YIELD.(%)
0.72

Company Details

Check out the key parameters of the company to understand the financial health and stock performance

Key Level

Resistance 1
1117.05
Resistance 2
1128.95
Support 1
1092.85
Support 2
1080.55

Moving Average

20 Days
1151.27
50 Days
1227.53
100 Days
1250.19
200 Days
1281.26
Growth in 3 years

Sales
30.01%

Sales Industry Avg
17.49%

PAT
155.57%

PAT Industry Avg
38.55%

Dec 2024
( in Cr.)
Sep 2024
( in Cr.)
Jun 2024
( in Cr.)
Mar 2024
( in Cr.)
FY 2024
( in Cr.)
Sales8,381.208,038.207,696.107,113.8028,011.10
Gross Profit2,345.702,314.402,263.201,972.908,671
Operating Profit00000
Profit Before Tax1,937.202,113.201,913.901,592.107,201
Tax533771.30521.50282.301,623.10
Profit After Tax1,404.201,341.901,392.401,309.805,577.90
Growth in 3 years

Total Asset Growth
34.25%

Total Liabilities growth
34.25%

Reserves Change
47.27%

Mar 2024
( in Cr.)
Mar 2023
( in Cr.)
Mar 2022
( in Cr.)
Mar 2021
( in Cr.)
Mar 2020
( in Cr.)
Share Capital83.4083.3083.2083.2083.10
Reserves And Surplus28,171.4023,202.8019,129.2017,558.5015,515.70
Investments4,930.504,985.802,615.902,211.802,677.80
Total Debt2,339.901,570.303,577.203,243.302,490.20
Total Liabilities30,594.7024,856.4022,789.6020,88518,089
Total Assets30,594.7024,856.4022,789.6020,88518,089
800%
2023
800%
2024 2025
2026


Relative to Sensex rtn in 3 year
30.24%

Relative to Nifty rtn in 3 year
22.09%



1 Year (%)2 Year (%)3 Year (%)
Dr Reddy`s Labs-122740
Bse Sensex02731
Nifty 5023133
Nifty 50034040

Peer Companies

A quick glance on how stocks from the same sector have performed along with some key parameters

Dr Reddy`s Labs
1,107.95
Change: 2.80 (0.25%)
1 Year return
-12.12%
Risk (Std Dev)
0.08%
PE Ratio
17.21066
MCap( in Cr.)
92,452.24
Sun Pharma.Inds.
1,683.45
Change: 6.60 (0.39%)
1 Year return
8.01%
Risk (Std Dev)
0.07%
PE Ratio
34.25244
MCap( in Cr.)
4,03,916.05
Divi`s Lab.
5,620.45
Change: -46.70 (-0.82%)
1 Year return
61.52%
Risk (Std Dev)
0.06%
PE Ratio
72.17827
MCap( in Cr.)
1,49,205.29
Cipla
1,461.90
Change: 7.60 (0.52%)
1 Year return
-0.64%
Risk (Std Dev)
0.04%
PE Ratio
23.65814
MCap( in Cr.)
1,18,065.23
Torrent Pharma.
3,056.05
Change: -40.45 (-1.31%)
1 Year return
14.72%
Risk (Std Dev)
0.06%
PE Ratio
55.58797
MCap( in Cr.)
1,03,425.97
View More

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

 

If I had made
investment of  
in
Months Ago
My investment would be worth 87,879.50 with a Loss of -12.12%

Our Research Reports

Stocks and sector-wise Research Reports by HDFC securities help you analyse, understand and take a informed investment decision.

Institutional Reports 14 Jan 2025 1:51 PM
The India Pharma & Healthcare sector is expected to see steady growth in Q3FY25E. We project sales/EBITDA growth of 11%/13% YoY for our coverage universe. Our assumptions are: (1) pharma coverage wil..
Institutional Reports 06 Nov 2024 6:51 AM
Titan: Consolidated jewellery sales (ex-bullion) grew 27% YoY to INR117.8bn (HSIE: in-line). Gold jewellery demand witnessed a step-up jump post the Jul-24 customs duty (CD) cut. This gold rush laste..
Institutional Reports 09 Oct 2024 9:00 PM
The India Pharma & Healthcare sector is expected to maintain its growth momentum in Q2FY25E. We project sales/EBITDA growth of 11%/15% YoY for our coverage universe. Our assumptions are: (1) Pharma c..
View More

Corporate Action

Find out the historical dividend payout and other corporate actions including bonus, stock split and rights issue etc.

D
2023
D
S
2024
2025

FnO

A snapshot on how the stock has performed in the derivatives segment on a real-time basis.

Dr Reddys Laboratories Ltd 1,105.50 Chg: -2.00(-0.18%) Expiry Month 27 Mar 2025
Day's Low
1,095.40
Day's High
1,110.00
Day’s Open
1,105.15
Prev Close
1,107.50
Volume
15,30,625
OI
98,56,250
OI Change (%)
-0.89
View More

News

Stay tuned to the latest developments and happenings in the company.

Dr. Reddy`s recalls Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL in US

Dr. Reddy`s Laboratories is recalling one Batch/Lot No: A1540076 of Levetiracetam in 0.75% Sodium Chloride Injection, 1,000 mg/100 mL (10 mg/m....

13 Mar 2025 18:46

Dr Reddys Laboratories allots 11,250 equity shares under ESOS

Dr Reddys Laboratories has allotted 11,250 equity shares under ESOS on 06 March 2025. Powered by Capital Market - Live News

06 Mar 2025 19:16

Dr Reddys Laboratories allots 20,155 equity shares under ESOS

Dr Reddys Laboratories has allotted 20,155 equity shares of Re.1/- each of the Company, fully paid up, on 14 February 2025, to eligible employees purs....

14 Feb 2025 18:24

Dr Reddy`s Laboratories consolidated net profit rises 2.38% in the December 2024 quarter

Net profit of Dr Reddy`s Laboratories rose 2.38% to Rs 1413.70 crore in the quarter ended December 2024 as against Rs 1380.90 crore during the previou....

23 Jan 2025 17:55

Dr Reddy`s Laboratories consolidated net profit declines 15.28% in the September 2024 quarter

Net profit of Dr Reddy`s Laboratories declined 15.28% to Rs 1255.70 crore in the quarter ended September 2024 as against Rs 1482.20 crore during the p....

05 Nov 2024 17:09

Dr Reddy`s Laboratories consolidated net profit declines 0.90% in the June 2024 quarter

Net profit of Dr Reddy`s Laboratories declined 0.90% to Rs 1392.40 crore in the quarter ended June 2024 as against Rs 1405.00 crore during the previou....

27 Jul 2024 16:55

View More
Subscribe for our
newsletter
Open Account Now